scholarly journals Photodynamic Therapy with Verteporfin for Choroidal Metastasis Refractory to Radiotherapy

2019 ◽  
Vol 12 (3) ◽  
pp. 861-865
Author(s):  
Raymond Zhou ◽  
David Reichstein
Keyword(s):  
Breast Cancer ◽  
Photodynamic Therapy ◽  
Metastatic Breast Cancer ◽  
Primary Breast Cancer ◽  
External Beam Radiotherapy ◽  
Metastatic Breast ◽  
Eye Disease ◽  
External Beam ◽  
Choroidal Metastasis

A 54-year old female with longstanding metastatic breast cancer was referred for management of choroidal metastases. She was first treated with external beam radiotherapy and experienced some response before later suffering progression of her eye disease. We then treated her using full fluence Photodynamic therapy (PDT) with Verteporfin, which resulted in regression of her lesions until she passed away due to other illnesses. This is the first documented successful application of PDT for choroidal metastasis from a primary breast cancer refractory to external beam radiotherapy.

Rapid and prolonged palliation of symptoms with improved quality of life (QOL) with endocrine therapy (anastrazole) in metastatic breast cancer (MBC)

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10767-10767
Author(s):  
J. Samuel ◽  
D. Osafo
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Lymph Node ◽  
Pleural Effusion ◽  
Endocrine Therapy ◽  
Primary Breast Cancer ◽  
Metastatic Breast ◽  
Electrolyte Imbalance ◽  
Axillary Lymphadenopathy ◽  
Post Menopausal

10767 Background: Efficacy of anastrazole in receptor positive post-menopausal MBC; rapid palliation of symptoms with improved QOL. Methods: Case Report: A 62 year old woman diagnosed with right breast cancer in 1995, stage IIB, underwent surgery, adjuvant chemotherapy, and tamoxifen for 5 years. In February 2004, a left supraclavicular lymph node (1 cm) was felt. Chest x-ray (CXR) showed blunting of right cardiophrenic angle. CT scan of the neck showed multiple left cervical lymph nodes. In April 2004, her condition deteriorated rapidly needing hospitalization. She developed 15 pound weight loss, anemia, anorexia, shortness of breath, dyspnea on exertion, dry cough, and chest pain. CXR showed large right pleural effusion needing multiple thoracentesis. Hemorrhagic exudative effusion was seen with negative cytology and cultures. She also developed multiple palpable left cervical and left axillary lymphadenopathy. Breast exam was normal. Mammogram was not diagnostic but ultrasound of breast showed a 2.5cm left breast mass, axillary lymphadenopathy and additional lesions in the breast. Left cervical lymph node biopsy showed metastatic adenocarcinoma favoring primary breast cancer. A diagnosis of 2nd primary breast cancer with metastasis was made. Within 1 week of palliative capecitabine, she was readmitted with significant mucositis, diarrhea, dehydration, dysphagia, electrolyte imbalance, and reaccumulation of right pleural effusion. She lost 35 lbs. in 4 months. She was aggressively resuscitated and also needed thoracocentesis. Markers from prior biopsy showed Estrogen receptor 20%, Progesterone receptor <5%, and HER 2 (Herceptest) 3+. Palliative hormonal therapy with anastrazole was started in July 2004. Results: Within 4 weeks, she improved significantly with disappearance of lymphadenopathy and resolution of effusion. Performance status improved to ECOG 0. She is continuing anastrazole, 17 months since the diagnosis of debilitating metastatic breast cancer. Conclusions: Anastrazole is approved for the treatment of hormone receptor positive post-menopausal MBC. We describe the efficacy of endocrine therapy (anastrazole) leading to rapid and meaningful palliation of symptoms with improved QOL. No significant financial relationships to disclose.

In vitro and in vivo effects of photodynamic therapy on metastatic breast cancer cells pre-treated with zoledronic acid

2014 ◽  
Vol 11 (3) ◽  
pp. 426-433
Author(s):  
Margarete K. Akens ◽  
Lisa Wise-Milestone ◽  
Emily Won ◽  
Joerg Schwock ◽  
Albert J.M. Yee ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Photodynamic Therapy ◽  
Metastatic Breast Cancer ◽  
Zoledronic Acid ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Metastatic Breast ◽  
In Vivo Effects

scholarly journals German Breast Group (GBG)

2006 ◽  
Vol 9 (S1) ◽  
pp. 138-165
Author(s):  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Primary Breast Cancer ◽  
Metastatic Breast ◽  
Phase Iii ◽  
Breast Cancer Patients ◽  
Phase Iii Study ◽  
Her 2 ◽  
Joint Study ◽  
Breast Group

This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by German Breast Group (GBG). Clinical trials include: A multi-center randomized Phase III study evaluating 4 cycles of docetaxel, doxorubicin and cyclophosphamide (TAC) versus 4 cycles of vinorelbine and capecitabine (NX) in patients not sufficiently responding to 2 cycles of TAC and 4 cycles of TAC versus 6 cycles of TAC in patients sufficiently responding to 2 cycles of TAC as preoperative treatment of locally advanced (T4 a-d, N0-3,M0) or operable (T ≥ 2 cm, N0-2,M0) primary breast cancer/GBG 24.A multi-center randomized Phase III study to compare capecitabine alone or in combination with trastuzumab in patients with HER-2 positive metastatic breast cancer and progression after previous treatment with trastuzumab (Treatment Beyond Progression, TBP). BIG 3-05-GBG26A Phase III multi-centre double blind randomized trial of celecoxib versus placebo in primary breast cancer patients. BIG 1-03-ICCG/C/20/01 - GBG27 (see also description under ICCG)Prospective Register Study of the German Adjuvant Breast Cancer Study Group (GABG) or Diagnosis and Treatment of Breast Cancer in Pregnancy / BIG 2–03, GBG 29.Ibandronate with or without capecitabine in elderly patients with early breast cancer – ICE – Study / BIG 4-04, GBG 32. (see also description under WSG)GAIN: German Adjuvant Intergroup Node-positive Study. A Phase III trial to compare ETC versus EC-TX and ibandronate versus observation in patients with node-positive primary breast cancer / GBG 33.A randomized, multi-center, open Phase III study comparing the postoperative use of zoledronic acid versus no treatment in patients with histological tumour residuals after preoperative anthracycline and taxane-containing chemotherapy for primary breast cancer (Neo-Adjuvant Trial Add-On) / GBG 36.Prospective randomized multi-center study to prevent chemotherapy-induced ovarian failure with the GnRH-agonist goserelin in young hormone-insensitive breast cancer patients receiving anthracycline-containing (neo-)adjuvant chemotherapy / GBG 37, ZORO-StudyA multi-centre Phase I–II study to investigate the combination of bendamustine with weekly paclitaxel as first or second line therapy in patients with anthracycline-pretreated metastatic breast cancer / GBG 38, Rita – Study.A multi-center Phase II study to determine the efficacy of capecitabine as first line monochemotherapy in patients with HER-2 negative metastatic breast cancer / GBG 39, Monica – Study.GeparQuattro: A randomized Phase III study exploring the efficacy of capecitabine given concomitantly or in sequence to EC – Doc with or without trastuzumab as neoadjuvant treatment of primary breast cancer. A joint study of GBG and AGO / GBG 40.Randomized study comparing 6 × FEC with 3 × FEC followed by 3 × docetaxel in high-risk node-negative patients with operable breast cancer: comparison of efficacy and evaluation of clinico-pathological and biochemical markers as risk selection criteria. A joint study of AGO, the EORTC Receptor and Biomarker Group, and the GBG (GBG 42 / NNBC 3-Europe).

scholarly journals Photodynamic therapy of intradermal metastatic breast cancer (literature review)

2019 ◽  
Vol 8 (3) ◽  
pp. 36-42
Author(s):  
R. I. Rakhimzhanova ◽  
N. A. Shanazarov ◽  
D. E. Turzhanova
Keyword(s):  
Breast Cancer ◽  
Photodynamic Therapy ◽  
Metastatic Breast Cancer ◽  
Therapeutic Effect ◽  
High Efficiency ◽  
Radiation Treatment ◽  
Metastatic Breast ◽  
Breast Metastases ◽  
The World ◽  
Promising Treatment

In recent years, an increase in the incidence of breast cancer has been observed throughout the world, and in 20% of cases, with the development of intradermal metastases. The possibilities of surgical and radiation treatment of intradermal breast metastases are quite limited, and the effectiveness of polychemotherapy using standard regimens does not exceed 22–27%, while the period of remission, in general, is only 2–3 months. Photodynamic therapy (PDT) is a promising treatment for intradermal metastases of breast cancer. The experience of using PDT in this nosology is quite limited, but the results show its high efficiency and safety. Thus, several Russian studies are devoted to assessing the effectiveness of PDT of intradermal breast metastases with Photolon, a chlorin series photosensitizer. According to the authors, the therapeutic effect was achieved in 85–97% of patients (the percentage of patients with full and partial effect was 73–85%). Studies on the effectiveness of PDT in patients with the same nosology using the Photosens photosensitizer show a slightly lower effectiveness – the therapeutic effect was achieved in 81.8% of cases, while the proportion of patients with full and partial effect was only about 50%. Several studies have been carried out abroad on models of metastatic breast cancer using new photosensitizers (e.g. sodium sinoporphyrin) and new combined PDT regimens (e.g. adjuvant PDT with fluorouracil or Capecitabine). The obtained results demonstrate the promise of new approaches: PDT with sodium sinoporphyrin inhibited the growth of both the tumor itself and its metastases; the use of adjuvant regimens led to an increase in the tumor cells differentiation in the animal model, the cessation of tumor and metastatic foci growth.

Sign in / Sign up

Export Citation Format

Share Document